Pathologist Review · February 2026
"I stopped second-guessing my Ki-67 reads within the first week."
Dr. Elena Reyes, MD, FCAP
Surgical Pathology · University Medical Center, Houston
18 years clinical practice · Subspecialty: Breast & GI oncology
Independent review. No compensation received. Platform access provided for evaluation only.
Read the case
The Problem
What the RFP doesn't ask about.
Procurement documents measure throughput and reagent cost. They don't measure the diagnostic friction that accumulates when a platform underperforms at the margins — where most of the difficult cases live.
Stain batch variability across sites
Our three-campus network was running the same IHC protocol and getting different H-scores. Pathologists at the satellite sites were calling equivocal cases differently from downtown. We couldn't tell if it was the reagent lot, the processor calibration, or the tissue fixation window — and neither could the vendor's technical rep.
±18%
Inter-site Ki-67 variability, pre-platform
"I was annotating discordant cases every Monday morning. That's not a workflow — that's a fire drill."
Turnaround pressure eroding diagnostic confidence
Breast tumor boards run on Thursdays. The expectation from oncology is a finalized IHC panel by Wednesday noon. When stain repeats push into Wednesday morning, you're not doing careful diagnostic work — you're triage-reading under pressure. That's when errors compound.
34%
Of cases required at least one repeat stain
"The repeat rate was the number I kept bringing to administration. Nobody wanted to hear it."
Technical support that disappears after installation
Every platform demo promises 24-hour support. What that usually means is a ticketing system and a callback from a field rep who's covering six accounts across two states. When your CDX2 antibody is failing on a Monday morning case and the tumor board is in 48 hours, you need someone who knows your instrument, not a script.
6 hrs
Average response time from previous vendor, critical issues
"The escalation path was a PDF. An actual PDF with a phone tree."
Before → After
Eighteen months of actual numbers.
These figures come from our departmental QA dashboard and the lab director's quarterly report to administration. I'm not rounding in either direction.
Before · Platform A (Previous)
Ki-67 inter-site CV
±18%
Flagged in 3 consecutive CAP inspections
Weekly repeat stain rate
34%
Consuming ~12 hrs/week of technologist time
Avg critical-issue response
6.2 hrs
Field rep callback, not on-site resolution
Tumor board deferrals (IHC-related)
2–3/month
Oncology team tracking and escalating to admin
After · Slide (Current)
Ki-67 inter-site CV
±4%
Within single-lab precision benchmarks
Weekly repeat stain rate
6%
Down from 34% — primarily tissue artifact, not stain failure
Avg critical-issue response
38 min
Remote diagnostics + dedicated account specialist
Tumor board deferrals (IHC-related)
0
14 consecutive months — confirmed in departmental QA log
"The number that convinced our lab director wasn't the cost-per-slide. It was zero tumor board deferrals for fourteen months. That's the number that oncology notices. That's the number that ends the conversation."
Dr. Elena Reyes — Q4 2025 departmental review presentation
The Comparison
Five criteria. Three platforms. One pathologist's notes.
Each cell below contains the metric and a brief annotation from my evaluation. Platform B and Platform C are identified by letter to keep the focus on data — contact me directly if you need the full vendor names for your RFP.
Evaluation Criterion
Slide
ReviewedCurrent platform
Platform B
Previous platform
Platform C
Evaluated, not adopted
Stain Consistency
Inter-site coefficient of variation across 3 campuses, same antibody clone, 90-day rolling average
±4% CV
Confirmed by our three-site QA dashboard. Reagent lot changes flagged automatically — no surprise drift.
±14% CV
Improved after a reagent reformulation in Q2, but still required manual lot-to-lot verification by senior staff.
±22% CV
Vendor attributed variability to fixation time differences. That may be true — but the platform offered no tooling to compensate.
Integration Time
Calendar days from signed contract to first clinical case signed out on the platform
18 days
Two validation runs, LIS interface go-live, and staff training completed inside three weeks. No overtime required.
47 days
LIS integration required a custom middleware build. The delay was communicated proactively — but it still delayed our go-live.
61 days
On-site engineer unavailable for 3 weeks post-install. Validation runs ran on a vendor-managed timeline, not ours.
Technical Support Responsiveness
Time to first substantive response on a Severity 1 issue (stain failure affecting same-day cases)
38 min avg
Remote diagnostics pulled instrument logs before the call ended. Resolution on first contact in 8 of 9 critical incidents over 18 months.
2.8 hrs avg
Field rep model — responsive, but geographically constrained. After-hours issues routed to a national call center.
6.2 hrs avg
Ticketing system only. No remote diagnostics capability. Escalation required a supervisor approval before dispatch.
Cost Per Slide
All-in reagent cost per IHC slide including controls, at our volume (approx. 2,400 IHC slides/month)
$4.20
Volume pricing locked for 36 months. Repeat stain rate of 6% means effective cost is closer to $4.45 — still the lowest net.
$3.85
Lowest reagent list price. But a 22% repeat rate brought effective cost to approximately $4.70 per reportable slide.
$5.10
Premium pricing with no volume incentive at our scale. Support contract priced separately — adds ~$0.40/slide equivalent.
Antibody Panel Breadth
Number of validated antibody clones available on-platform, as of February 2026
340+ clones
Covered our full breast, GI, and hematopathology panel with validated protocols. Two custom validations completed in under 10 days.
280 clones
Strong core panel. Gaps in some niche hematology markers required send-out for 3 of our low-volume antibodies.
195 clones
Adequate for a general surgical pathology practice. Insufficient for our subspecialty oncology volume without supplemental platforms.
All figures from Dr. Reyes's departmental QA records, February 2024 – February 2026. Cost-per-slide calculated at 2,400 IHC slides/month including controls and failed runs.
Opens Slide's vendor page. No form, no tracking pixel from this site.
Dr. Elena Reyes, MD, FCAP
Surgical Pathology · University Medical Center
Houston, TX · 18 years practice
Independent review. No financial relationship with Slide Inc. Platform access provided for evaluation only.
The Conclusion
"If a colleague asked me in the break room — not in a committee meeting, not on an evaluation form — I would tell them exactly what I told our lab director: the platform that reduced my repeat rate from 34% to 6% and kept fourteen consecutive tumor boards on schedule is not a hard recommendation to make."
— Dr. Reyes, February 2026
18 mo
Evaluation period
43,200
IHC slides reviewed
0
Tumor board deferrals
Reviewed by Dr. Elena Reyes, MD, FCAP
18-month independent evaluation · University Medical Center, Houston